Navigation Links
Incisive Surgical Announces Breakthrough Peer Review Clinical Study
Date:1/17/2012

MINNEAPOLIS, Jan. 17, 2012 /PRNewswire/ -- Incisive Surgical, Inc. today announced a peer-reviewed publication of a profound clinical study. The study, titled "Skin Closure With Subcuticular Absorbable Staples After Cesarean Section Is Associated With Decreased Analgesic Use," was published online by the Archives of Gynecology & Obstetrics Journal in October 2011. The authors, Drs. Joshua Nitsche (Mayo Clinic College of Medicine, Rochester, MN) and Thomas Howe (District One Hospital, Fairbault, MN), concluded that "our results suggest that the use of subcuticular absorbable staples for skin closure at the time of cesarean section may lead to less in-hospital analgesic use … are associated with less pain immediately post-operatively when pain can be the most difficult to control… [and] would result in a cost savings of approximately $200 per patient even after considering the higher cost of the absorbable staple device." The unique INSORB Absorbable Skin Stapling Technology is a revolutionary new skin closure technology that places an absorbable staple entirely underneath the skin to close surgical incisions. Patients now have a more comfortable, convenient and cosmetic choice for rapid skin closure. This unique device has won several national awards, including the 2006 Wall Street Journal Technology Innovation of the Year Award for medical devices. Incisive Surgical is the only company in the world that offers this technology and has sold over 750,000 INSORB® Absorbable Skin Staplers since the product launch in January 2005.

"The results of this peer-review clinical study are profound," said John L. Shannon, Jr., president and chief executive officer of Incisive Surgical. "The INSORB Staple does not pierce and puncture the outside of the patient's skin like metal skin staples, and this study suggests that the INSORB Skin Closure Technology may lead to higher patient satisfaction with reduced costs."

In addition, the Company announced that the U.S. Patent and Trademark Office (USPTO) issued the Company two additional key patents for its proprietary INSORB® Absorbable Skin Stapling Technology during the fourth quarter of 2011. The allowed claims for these two patents include comprehensive subject matter covering the method and apparatus of the INSORB Skin Closure technology, as well as the design of the absorbable staple. The Company holds nine INSORB Patents – seven in the United States and two in Japan – with two patents pending in Europe.

The INSORB Absorbable Skin Stapler offers the speed of metal skin staplers with the cosmetic results and comfort of absorbable sutures. The INSORB Stapler uses bioabsorbable staples that are placed underneath the skin and dissolve in the body within a matter of months. The staples, which are comprised of the same material as the leading bioabsorbable sutures, break down naturally, thereby eliminating the anxiety, pain, cost and inconvenience of post-operative staple removal.

About Incisive Surgical

Incisive Surgical, Inc. is a privately-held medical device company established to develop innovative cost-effective patient-centric solutions for skin closure. For more information or to request a media kit, contact info@insorb.com or visit www.insorb.com. To learn more about skin closure options and patients' rights, visit www.ihatemetalskinstaples.com.

John L. Shannon Jr.
952-591-2543, ext. 18
shannon@insorb.com

 

 

 

 


'/>"/>
SOURCE Incisive Surgical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Incisive Surgical Issued Notice of Allowance for Key Absorbable Skin Stapler Patent
2. Incisive Surgical Launches New National Patient Advocacy Campaign -- Eliminate Traumatic Metal Skin Staples for Routine Skin Closure
3. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
5. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
6. New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems
7. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
8. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
9. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
10. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
11. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... , July 26, 2017 The Galien Foundation ... Galien USA Award Nominees. Counted among ... Galien Award recognizes outstanding biomedical and technology product achievement that ... To qualify, each candidate must be U.S. Food and ... years and demonstrate tremendous potential to impact human health. Sales ...
(Date:7/24/2017)... IBM (NYSE: IBM ) has been recognized as a ... for the fourth year in a row. 1 ... the Leaders quadrant have the highest scores for their Ability ... Leaders quadrant has the market share, credibility, and marketing and ... These vendors demonstrate a clear understanding of market needs; they ...
(Date:7/21/2017)... SPRING, Md. and RESEARCH TRIANGLE ... United Therapeutics Corporation (NASDAQ: UTHR ) announced ... financial results before the market opens on Thursday, July ... Therapeutics will host a teleconference on Thursday, July 27, ... accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  ...
Breaking Medicine Technology:
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be partnering with Six ... schedule an appointment online in real time,” said Keith English, LocalMed CEO. “Allowing patients ... will bring more Six Month Smiles patients to their providers.” , Each month, over ...
(Date:7/26/2017)... ... July 26, 2017 , ... IDC-Eating Disorder Care ... the treatment program located in Royal Oak, Michigan. IDC, formerly known as ... focused on providing the highest standards in the field of eating disorder treatment in ...
(Date:7/26/2017)... ... July 26, 2017 , ... The Amnesty Rally 2017 will be held on ... 3313 Bernstein Park Drive in Monroe (adjacent to the Louisiana Purchase Gardens & Zoo). ... gun violence throughout Monroe. Citizens can turn in unregistered, illegally-held and imitation guns to ...
(Date:7/26/2017)... ... July 26, 2017 , ... BioPlus Specialty Pharmacy ... updated version of the HCV Treatment Path app (version 4.4.0) to keep health ... (HCV) infection. All of the latest HCV medications are included in this app, ...
(Date:7/25/2017)... ... July 25, 2017 , ... “Now Hiring!” is a popular phrase at ... company has achieved record-breaking sales for over 30 consecutive years and now plans to ... The upcoming year offers excitement and growth at HDIS, following the company’s acquisition by ...
Breaking Medicine News(10 mins):